Literature DB >> 15660470

Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis.

Peter E Lipsky1.   

Abstract

The advent of biologic therapy has not only provided the opportunity for better care of patients with rheumatoid arthritis (RA), but also has permitted a better understanding of the pathogenesis of this autoimmune/inflammatory disease. The capacity of these agents to suppress signs and symptoms as well as radiographic progression of RA strongly indicates that they can alter the course of the disease. Appropriate analysis of the effect of biologics should provide new insight into the role of the specific targeted molecules in rheumatoid inflammation, and provide information about means to optimize therapy with these highly potent therapeutics.

Entities:  

Mesh:

Year:  2005        PMID: 15660470

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  2 in total

1.  Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis.

Authors:  D Baeten; J Houbiers; E Kruithof; B Vandooren; F Van den Bosch; A M Boots; E M Veys; A M M Miltenburg; F De Keyser
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

2.  Biological drug use: US perspectives on indications and monitoring.

Authors:  J J Cush
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.